Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Administrative Prevalence and Healthcare Utilization of Pediatric Cystic Fibrosis in a Middle-Income Country: A 10-Year Analysis of National Administrative Data.

Pediatric pulmonology·2026
Same author

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2026
Same author

Correction: The KrasG12D;Trp53fl/fl murine model of undifferentiated pleomorphic sarcoma is macrophage dense, lymphocyte poor, and resistant to immune checkpoint blockade.

PloS one·2026
Same author

Neuroinvasive eastern equine encephalitis in a previously healthy 56-year-old woman.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2026
Same author

Forecasting Trends in Androgen Deprivation Therapy Intensification for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Population-Based Cohort and Time-Series Analysis.

Current oncology (Toronto, Ont.)·2026
Same author

Real-World Effectiveness of Capecitabine and Temozolomide Across Endocrine and Neuroendocrine Neoplasm Subtypes (ENENs): A Population-Based Cohort Study from Alberta, Canada (2011-2021).

Current oncology (Toronto, Ont.)·2026

Related Experiment Video

Updated: Jun 4, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

Real-world Clinical Outcomes and Prognostic Factors in Neuroendocrine Prostate Cancer.

Richard Gagnon1, Ealia Khosh Kish2, Sarah Cook1

  • 1Tom Baker Cancer Centre, Calgary, Alberta, Canada.

Clinical Genitourinary Cancer
|December 17, 2024
PubMed
Summary

Neuroendocrine prostate cancer (NEPC) is underdiagnosed and linked to poorer outcomes. Anemia and high neutrophil-lymphocyte ratio (NLR) predict worse survival in NEPC patients.

Keywords:
Aggresive variant prostate cancerBiomarkersNEPCmCRPC

More Related Videos

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.5K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K

Related Experiment Videos

Last Updated: Jun 4, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.5K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K

Area of Science:

  • Oncology
  • Pathology
  • Prostate Cancer Research

Background:

  • Neuroendocrine prostate cancer (NEPC) includes pure NEPC and mixed histology tumors.
  • NEPC is associated with a poor prognosis, but outcome data are limited.
  • This impacts risk stratification and clinical decision-making for prostate cancer patients.

Purpose of the Study:

  • To investigate the underdiagnosis of NEPC in pathology reports.
  • To evaluate the clinical outcomes and survival rates for NEPC.
  • To identify prognostic factors associated with survival in NEPC.

Main Methods:

  • Retrospective analysis of high-grade prostate cancer cases with NEPC features.
  • Calculation of median overall survival (OS) by stage and castration sensitivity.
  • Multivariate analysis to assess prognostic factors and survival outcomes.

Main Results:

  • Only 25.9% of NEPC cases were documented in original reports; 91.9% had mixed pathology.
  • Median OS varied significantly by stage and castration sensitivity, with metastatic castration-resistant NEPC having the shortest survival (9.6 months).
  • Anemia and elevated neutrophil-lymphocyte ratio (NLR) were significant predictors of increased mortality (HR: 1.66 and 1.51, respectively).

Conclusions:

  • NEPC is frequently underdiagnosed in pathology specimens.
  • NEPC confers a poorer prognosis than adenocarcinoma, with rapid progression and limited survival after first-line metastatic treatment.
  • Anemia and elevated NLR are associated with poor survival in NEPC, highlighting potential biomarkers.